Andrew J Beavil Selected Research

Allergens

11/2018	Structure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognition.
1/2018	Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody.
7/2014	A tool kit for rapid cloning and expression of recombinant antibodies.
9/2012	Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.
7/2012	Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI.
4/2005	Disulfide linkage controls the affinity and stoichiometry of IgE Fcepsilon3-4 binding to FcepsilonRI.
1/2003	The biology of IGE and the basis of allergic disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew J Beavil Research Topics

Disease

10	Neoplasms (Cancer) 01/2023 - 09/2007
6	Hypersensitivity (Allergy) 09/2012 - 02/2002
4	Immediate Hypersensitivity 11/2018 - 01/2003
3	Melanoma (Melanoma, Malignant) 01/2023 - 04/2011
3	Asthma (Bronchial Asthma) 11/2017 - 10/2011
3	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 09/2007
2	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2017
2	Inflammation (Inflammations) 01/2021 - 04/2005
2	Breast Neoplasms (Breast Cancer) 09/2012 - 06/2009
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2023
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2023
1	Autoimmune Diseases (Autoimmune Disease) 01/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2021
1	Anaphylaxis (Anaphylactic Shock) 09/2012
1	Seasonal Allergic Rhinitis (Hay Fever) 09/2012
1	Disease Progression 04/2011
1	Rheumatoid Arthritis 01/2009
1	Carcinoma (Carcinomatosis) 09/2007

Drug/Important Bio-Agent (IBA)

20	Immunoglobulin E (IgE)IBA 01/2023 - 02/2002
9	AntibodiesIBA 01/2018 - 01/2003
8	Immunoglobulin G (IgG)IBA 01/2017 - 07/2002
7	AllergensIBA 11/2018 - 01/2003
5	AntigensIBA 01/2023 - 02/2008
3	Fc Receptors (Fc Receptor)IBA 01/2023 - 01/2017
3	Folic Acid (Vitamin M)FDA LinkGeneric 01/2017 - 09/2007
2	chondroitin sulfate proteoglycan 4IBA 01/2023 - 01/2017
2	Monoclonal AntibodiesIBA 01/2017 - 04/2011
2	Proteins (Proteins, Gene)FDA Link 04/2012 - 10/2011
2	Carrier Proteins (Binding Protein)IBA 02/2008 - 09/2007
2	IgE Receptors (Fc epsilon RI)IBA 02/2008 - 09/2007
1	Toll-Like Receptor 7IBA 01/2023
1	Imiquimod (Aldara)FDA LinkGeneric 01/2023
1	Toll-Like Receptor 9IBA 01/2023
1	Toll-Like Receptor AgonistsIBA 01/2023
1	Cell Surface ReceptorsIBA 01/2021
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2017
1	CalciumIBA 01/2017
1	Antiparasitic Agents (Antiparasitics)IBA 01/2017
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2017
1	aspercyclide AIBA 10/2011
1	Ether (Diethyl Ether)IBA 10/2011
1	human ERBB2 proteinIBA 06/2009
1	Trastuzumab (Herceptin)FDA Link 06/2009
1	Galactose (Galactopyranose)FDA LinkGeneric 01/2009
1	CarbohydratesIBA 01/2009
1	Galectin 3 (LGALS3)IBA 02/2008
1	Peptides (Polypeptides)IBA 02/2002

Therapy/Procedure

5	Immunotherapy 01/2023 - 09/2007
3	Therapeutics 01/2023 - 04/2012
1	Injections 01/2023
1	Topical Administration 01/2023